Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate (DMBA-TPA)
December 19th, 2019
Two-stage skin carcinogenesis is induced by two topically applied chemicals. A mutagen 7,12-dimethylbenz[a]anthracene) causes mutations in the epidermal cells and a continuous application of general growth stimulator 12-O-tetradecanoyl phorbol-13-acetate accelerates skin papilloma formation.
This two step skin cancer model enables the study of the role of inflammation in skin cancer and allows the study the tumor initiation as a separate process from tumor progression. The tumor formation in this model is chemically induced and allows the use of knockout strains to study the effects of environmental factors or therapeutic candidates. The model is well suited for studying the role of immune system and angiogenesis in cancer.
It demonstrates a similar disease pathology to squamous cell carcinoma in human patients. Although this method is relatively easy to conduct, accurate timing is essential. It's also important to take appropriate safety measures when handling DMBA, which is a carcinogen.
Before beginning the experiment, house any aggressive seven to nine week old mice in separate cages to avoid fighting and skin lesions. For skin papilloma induction, first shave the back skins of the experimental animals and weigh the mice individually. 48 hours after shaving, use a pipette to apply 50 micrograms of DMBA in 200 microliters of acetone onto the shaved area of each anesthetized mouse.
For skin papilloma promotion, seven days after DMBA application treat the skin with five micrograms of TPA in 200 microliters of acetone two times a week through the end of the experiment. Examine the animals for papillomas and photograph and record the size of each individual papilloma on a map every week. A palpable mass greater than one millimeter in diameter is considered a papilloma if it remains longer than one week.
When the tumor response reaches a plateau, harvest the appropriate sample material from the animals 24 hours after the last TPA application and collection full thickness pieces of skin for immunohistochemical analysis. Use a biopsy punch to collect skin pieces from papilloma and non-papilloma skin samples for gene expression and or protein anaylses and use a scalpel to collect pieces from papilloma and non-papilloma skin for immunohistochemical analysis. Then collect the skin draining lymph nodes and a piece of the spleen for flow cytometric analysis as desired.
A statistically significant difference in the papilloma free time and in the number of papillomas between the experimental groups is typically observed in the DMBA TPA tumor model. Histological analyses are suitable for studying the structure of the papillomas, the morphology of the skin, or the infiltration of immune cells of interest. It is essential to apply the DMBA and TPA evenly on the skin and to apply TPA in consistent intervals.
It also important to count the papillomas regularly. The mechanisms that affect the number and time of tumor formation can be studied using different methods, including immunohistochemistry, flow cytometry, quantitative PCR, and protein analysis. This conventional technique can be easily adapted and applied to study the effects of different genes, environmental factors, or therapeutics of interest on tumor initiation and progression.
Caution is required when performing the technique since DMBA is carcinogenic and acetone evaporates quickly. A suitable breathing mask and the use of flow cabinet are recommended.
View the full transcript and gain access to thousands of scientific videos
Overview
This study presents a two-stage skin carcinogenesis model that allows researchers to investigate the role of inflammation in skin cancer. The model utilizes a mutagen and a growth stimulator to induce tumor formation, providing insights into tumor initiation and progression.
Key Study Components
Area of Science
- Oncology
- Carcinogenesis
- Inflammation
Background
- Two-stage skin carcinogenesis involves a mutagen and a growth stimulator.
- The model is relevant for studying squamous cell carcinoma.
- Accurate timing and safety measures are critical in the experimental setup.
- Knockout strains can be used to explore environmental and therapeutic factors.
Purpose of Study
- To investigate the mechanisms of tumor initiation and progression.
- To assess the role of the immune system in skin cancer.
- To evaluate angiogenesis in the context of chemically induced tumors.
Methods Used
- Topical application of 7,12-dimethylbenz[a]anthracene (DMBA).
- Continuous application of 12-O-tetradecanoyl phorbol-13-acetate (TPA).
- Use of knockout strains for environmental factor studies.
- Monitoring tumor formation and progression over time.
Main Results
- The model successfully mimics human squamous cell carcinoma pathology.
- Inflammation plays a significant role in tumor development.
- Accurate timing is essential for reproducibility of results.
- Safety protocols are necessary when handling carcinogenic substances.
Conclusions
- The two-stage model is effective for studying skin cancer mechanisms.
- It provides a platform for testing therapeutic candidates.
- Further research can enhance understanding of cancer biology.
Frequently Asked Questions
Executive Industry Relevance
The DMBA-TPA two-stage skin carcinogenesis model provides a reliable platform for dissecting tumor initiation and progression in preclinical oncology research. Its reproducibility and quantitative readouts support mechanistic de-risking of inflammatory pathways and immune-mediated tumor promotion. This enables data-driven go/no-go decisions in early discovery and portfolio prioritization for dermatologic and immuno-oncology programs.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of tumor initiation versus progression using temporally separated chemical insults.
- Scientific Value: Supports functional validation of targets in inflammation-driven carcinogenesis via knockout strain analysis.
- Scientific Value: Facilitates mechanistic de-risking by isolating immune cell infiltration and angiogenic contributions to tumor formation.
Screening & Assay Development
- Operational Value: Generates standardized, quantifiable papilloma counts and growth metrics for compound screening.
- Operational Value: Delivers reproducible time-to-tumor and multiplicity readouts suitable for assay standardization.
- Operational Value: Supports scalable evaluation of therapeutic candidates affecting initiation or promotion stages.
Translational & Preclinical Research
- Translational Value: Models human squamous cell carcinoma pathology, enabling relevance to dermatologic oncology indications.
- Translational Value: Links inflammatory mechanisms to tumor progression, supporting biomarker-aligned preclinical validation.
- Translational Value: Provides a platform for testing immunomodulatory and anti-angiogenic agents in a physiologically relevant context.
Pipeline & Workflow Integration
The model fits within the discovery continuum from target validation through preclinical efficacy testing, particularly for immuno-oncology and inflammatory pathway modulation.
- Discovery Biology: Enables hypothesis testing of gene-environment interactions in carcinogenesis using inducible or constitutive knockout models.
- Screening: Delivers quantitative endpoints such as papilloma latency and burden for dose-response and lead optimization.
- Analytics: Generates histopathological, flow cytometric, and molecular readouts to correlate phenotypic outcomes with mechanism.
- Translational Research: Supports continuity from mechanistic discovery to preclinical validation via shared inflammatory and angiogenic axes.
- Enterprise Reuse: Establishes a reusable inflammatory carcinogenesis platform for cross-indication screening in skin and epithelial cancers.
Operational & Enterprise Impact
- Scientific Value: Reduces mechanistic ambiguity by decoupling initiation and promotion phases in tumor development.
- Operational Value: Ensures reproducibility through standardized chemical dosing, timing, and safety-controlled application.
- Strategic Value: Improves capital efficiency by enabling early de-risking of targets in inflammation-driven tumor models.
- Portfolio Impact: Informs risk-adjusted advancement decisions based on tumor-free survival and progression metrics.
Implementation Considerations
- Requires expertise in handling carcinogens and administering topical treatments in rodent models.
- Dependent on ventilation and PPE infrastructure due to DMBA volatility and carcinogenicity.
- Necessitates standardized animal husbandry to prevent confounds from fighting or skin lesions.
- Requires training in consistent tumor measurement and longitudinal tracking for reliable endpoints.
- Limited to cutaneous or accessible epithelial surfaces, restricting use to topical or mucosal delivery studies.
